These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 30707635)

  • 1. Immunological basis for enhanced immunity of nanoparticle vaccines.
    Kelly HG; Kent SJ; Wheatley AK
    Expert Rev Vaccines; 2019 Mar; 18(3):269-280. PubMed ID: 30707635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
    Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
    ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle vaccines against viral infections.
    Sulczewski FB; Liszbinski RB; Romão PRT; Rodrigues Junior LC
    Arch Virol; 2018 Sep; 163(9):2313-2325. PubMed ID: 29728911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
    Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
    J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle vaccines.
    Zhao L; Seth A; Wibowo N; Zhao CX; Mitter N; Yu C; Middelberg AP
    Vaccine; 2014 Jan; 32(3):327-37. PubMed ID: 24295808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
    Engeroff P; Bachmann MF
    Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanovaccine: an emerging strategy.
    Das A; Ali N
    Expert Rev Vaccines; 2021 Oct; 20(10):1273-1290. PubMed ID: 34550859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
    Martins KAO; Cooper CL; Stronsky SM; Norris SLW; Kwilas SA; Steffens JT; Benko JG; van Tongeren SA; Bavari S
    EBioMedicine; 2016 Jan; 3():67-78. PubMed ID: 26870818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of adenoviral vaccine vectors with altered antigen presentation capabilities.
    Neukirch L; Fougeroux C; Andersson AC; Holst PJ
    Expert Rev Vaccines; 2020 Jan; 19(1):25-41. PubMed ID: 31889453
    [No Abstract]   [Full Text] [Related]  

  • 11. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particle vaccines: immunology and formulation for clinical translation.
    Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
    Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale.
    Rosenthal JA; Chen L; Baker JL; Putnam D; DeLisa MP
    Curr Opin Biotechnol; 2014 Aug; 28():51-8. PubMed ID: 24832075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.
    Grenfell RF; Shollenberger LM; Samli EF; Harn DA
    Clin Vaccine Immunol; 2015 Mar; 22(3):336-43. PubMed ID: 25609075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platform for the generation of oral vaccines based on protozoan surface proteins.
    Serradell MDC; Rupil LL; Luján HD
    Medicina (B Aires); 2019; 79(Spec 6/1):559-563. PubMed ID: 31864226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid.
    Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; El-Baky NA; Redwan EM
    Hum Antibodies; 2018 Feb; 26(2):75-85. PubMed ID: 29171990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.
    Dykman LA
    Expert Rev Vaccines; 2020 May; 19(5):465-477. PubMed ID: 32306785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology in vaccine delivery.
    Peek LJ; Middaugh CR; Berkland C
    Adv Drug Deliv Rev; 2008 May; 60(8):915-28. PubMed ID: 18325628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond antigens and adjuvants: formulating future vaccines.
    Moyer TJ; Zmolek AC; Irvine DJ
    J Clin Invest; 2016 Mar; 126(3):799-808. PubMed ID: 26928033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.